The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...

ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B, and placental growth factor.

Aflibercept 8mg late-breaking data presented at Retina Society in diabetic macular edema and wet age-related macular degeneration. News release. Regeneron Pharmaceuticals, Inc. November 4, 2022.

Aflibercept is clearly an option for patients who are showing an incomplete anatomic response to other anti-VEGF agents," he noted. Dr. Recchia and colleagues presented results from a series of ...

--Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for Priority Review the Biologics License Application for aflibercept 8 mg for treatment ...

It agreed that aflibercept as well as other anti-VEGF treatments were a substantial improvement over previous treatments, and considered that this improvement applied to the class of drugs. In ...

EYLEA® (aflibercept) 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO ...